Skip Nav Destination
Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease
Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease
Clinical Trials & Observations
Brief Report
Mylène Camus,Sandrine Hirschi,Grégoire Prevot,Marie-Pierre Chenard,Hervé Mal,Marc Stern,Martine Reynaud-Gaubert,Julia Gilhodes,Odile Burlet-Schiltz,Pierre Brousset,Magali Colombat
GENE THERAPY
LYMPHOID NEOPLASIA
Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites
Clinical Trials & Observations
Jeffrey I. Cohen,Irini Manoli,Kennichi Dowdell,Tammy A. Krogmann,Deborah Tamura,Pierce Radecki,Wei Bu,Siu-Ping Turk,Kelly Liepshutz,Ronald L. Hornung,Hiva Fassihi,Robert P. Sarkany,Lori L. Bonnycastle,Peter S. Chines,Amy J. Swift,Timothy G. Myers,Melissa A. Levoska,John J. DiGiovanna,Francis S. Collins,Kenneth H. Kraemer,Stefania Pittaluga,Elaine S. Jaffe
There is a Blood Commentary on this article in this issue.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Clinical Trials & Observations
Ian W. Flinn,John G. Gribben,Martin J. S. Dyer,William Wierda,Michael B. Maris,Richard R. Furman,Peter Hillmen,Kerry A. Rogers,Swaminathan Padmanabhan Iyer,Anne Quillet-Mary,Loic Ysebaert,Harriet S. Walter,Maria Verdugo,Christian Klein,Huang Huang,Yanwen Jiang,Gerard Lozanski,Daniela Soriano Pignataro,Kathryn Humphrey,Mehrdad Mobasher,Thomas J. Kipps
There is a Blood Commentary on this article in this issue.
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Rebecca A. Luchtel,Michael T. Zimmermann,Guangzhen Hu,Surendra Dasari,Manli Jiang,Naoki Oishi,Hailey K. Jacobs,Yu Zeng,Tanya Hundal,Karen L. Rech,Rhett P. Ketterling,Jeong-Heon Lee,Bruce W. Eckloff,Huihuang Yan,Krutika S. Gaonkar,Shulan Tian,Zhenqing Ye,Marshall E. Kadin,Jagmohan Sidhu,Liuyan Jiang,Jesse Voss,Brian K. Link,Sergei I. Syrbu,Fabio Facchetti,N. Nora Bennani,Susan L. Slager,Tamas Ordog,Jean-Pierre Kocher,James R. Cerhan,Stephen M. Ansell,Andrew L. Feldman
TRANSPLANTATION
LETTERS TO BLOOD
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Clinical Trials & Observations
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation
Giada Rotunno,Carmela Mannarelli,Giada Brogi,Annalisa Pacilli,Francesca Gesullo,Francesco Mannelli,Sara Fiaccabrino,Benedetta Sordi,Chiara Paoli,Ilaria Marone,Elisa Rumi,Rossella Manfredini,Giovanni Barosi,Mario Cazzola,Alessandro M. Vannucchi,Paola Guglielmelli
BLOOD WORK
-
Cover Image
Cover Image
Eosinophilic extracellular amorphous Congo red–negative deposits admixed with some plasma cells without atypia are the histological hallmark of pulmonary light chain deposition disease (LCDD), an entity clinically and molecularly distinct from systemic LCDD. See the article by Camus et al on page 2741.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals